{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:41:22Z","timestamp":1793900482987,"version":"4.8.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recently, ferroptosis has emerged as a pathogenic mechanism that drives metabolic dysfunction-associated steatohepatitis (MASH); however, the upstream triggers and their relevance to fibrosis remain poorly understood. Here we identified dietary cholesterol-induced ferroptosis and the downregulation of peroxisome proliferator-activated receptor delta (PPAR\u03b4) as central drivers of MASH pathogenesis. To investigate this, human liver samples and cholesterol-enriched dietary murine models of MASH were examined in parallel with mechanistic studies in hepatocytes and hepatic stellate cells (HSCs). Cholesterol-induced MASH was associated with pronounced hepatic lipid peroxidation and the selective downregulation of PPAR\u03b4. The loss of PPAR\u03b4 disrupted redox homeostasis and sensitized hepatocytes to ferroptosis, whereas exosomal double-stranded DNA released from ferroptotic hepatocytes activated STING\u2013TBK1\u2013IRF3 and induced expression of profibrotic genes in HSCs. These effects were reversed by either overexpression of hepatocyte-specific PPAR\u03b4 or pharmacologic treatment with DN203316, a novel and highly selective PPAR\u03b4 agonist. In vivo, DN203316 mitigated ferroptosis, inflammation and fibrosis without inducing metabolic derangement. These findings were substantiated by clinical data demonstrating a marked increase in lipid peroxidation and STING-driven HSC activation in liver tissues from patients with MASH. In conclusion, PPAR\u03b4 is a key regulator of cholesterol-induced ferroptosis and exosome-mediated fibrogenic signaling in MASH. DN203316 offers a promising therapeutic strategy to suppress ferroptosis, disrupt hepatocyte\u2013HSC crosstalk and attenuate disease progression.<\/jats:p>","DOI":"10.1038\/s12276-026-01740-0","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:37:35Z","timestamp":1780659455000},"page":"1900-1913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["DN203316, a novel PPAR\u03b4 agonist, suppresses ferroptotic signaling and fibrogenesis in metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1038","volume":"58","author":[{"given":"Ye Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da Young","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihyang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Hwa","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonghwa","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6060-0508","authenticated-orcid":false,"given":"Jungwook","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-6437","authenticated-orcid":false,"given":"Yeon-Kyung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8403-1298","authenticated-orcid":false,"given":"Keun-Gyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"1740_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan, W. K. et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J. Obes. Metab. Syndr. 32, 197\u2013213 (2023).","journal-title":"J. Obes. Metab. Syndr."},{"key":"1740_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.4093\/dmj.2024.0541","volume":"48","author":"J Bae","year":"2024","unstructured":"Bae, J. et al. Metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus: a review and position statement of the fatty liver research group of the Korean Diabetes Association. Diabetes Metab. J. 48, 1015\u20131028 (2024).","journal-title":"Diabetes Metab. J."},{"key":"1740_CR3","doi-asserted-by":"publisher","first-page":"1433857","DOI":"10.3389\/fcell.2024.1433857","volume":"12","author":"R Sandireddy","year":"2024","unstructured":"Sandireddy, R. et al. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front. Cell Dev. Biol. 12, 1433857 (2024).","journal-title":"Front. Cell Dev. Biol."},{"key":"1740_CR4","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1016\/j.jtha.2023.06.017","volume":"21","author":"D Swan","year":"2023","unstructured":"Swan, D. et al. The prothrombotic tendency of metabolic-associated fatty liver disease. J. Thromb. Haemost. 21, 3045\u20133055 (2023).","journal-title":"J. Thromb. Haemost."},{"key":"1740_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1740_CR6","doi-asserted-by":"publisher","first-page":"e16186","DOI":"10.1111\/liv.16186","volume":"45","author":"D Linden","year":"2025","unstructured":"Linden, D., Tesz, G. & Loomba, R. Targeting PNPLA3 to treat MASH and MASH related fibrosis and cirrhosis. Liver Int. 45, e16186 (2025).","journal-title":"Liver Int."},{"key":"1740_CR7","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/apt.17930","volume":"59","author":"SK Bansal","year":"2024","unstructured":"Bansal, S. K. & Bansal, M. B. Pathogenesis of MASLD and MASH\u2014role of insulin resistance and lipotoxicity. Aliment. Pharmacol. Ther. 59, S10\u2013S22 (2024).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1740_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/1878-0261.13685","volume":"19","author":"M Karin","year":"2025","unstructured":"Karin, M. & Kim, J. Y. MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives. Mol. Oncol. 19, 275\u2013294 (2025).","journal-title":"Mol. Oncol."},{"key":"1740_CR9","doi-asserted-by":"publisher","first-page":"17514","DOI":"10.3390\/ijms242417514","volume":"24","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. Mitochondrial dysfunction in metabolic dysfunction fatty liver disease (MAFLD). Int. J. Mol. Sci. 24, 17514 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1740_CR10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.tem.2016.11.006","volume":"28","author":"NE Sunny","year":"2017","unstructured":"Sunny, N. E., Bril, F. & Cusi, K. Mitochondrial Adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies. Trends Endocrinol. Metab. 28, 250\u2013260 (2017).","journal-title":"Trends Endocrinol. Metab."},{"key":"1740_CR11","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00535-012-0739-0","volume":"48","author":"S Tanaka","year":"2013","unstructured":"Tanaka, S. et al. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J. Gastroenterol. 48, 1249\u20131258 (2013).","journal-title":"J. Gastroenterol."},{"key":"1740_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4093\/dmj.2023.0350","volume":"48","author":"I Jung","year":"2024","unstructured":"Jung, I., Koo, D. J. & Lee, W. Y. Insulin resistance, non-alcoholic fatty liver disease and type 2 diabetes mellitus: clinical and experimental perspective. Diabetes Metab. J. 48, 327\u2013339 (2024).","journal-title":"Diabetes Metab. J."},{"key":"1740_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.freeradbiomed.2025.02.017","volume":"230","author":"B Lin","year":"2025","unstructured":"Lin, B. et al. Regular exercise alleviates metabolic dysfunction-associated steatohepatitis through rescuing mitochondrial oxidative stress and dysfunction in liver. Free Radic. Biol. Med. 230, 163\u2013176 (2025).","journal-title":"Free Radic. Biol. Med."},{"key":"1740_CR14","doi-asserted-by":"publisher","first-page":"1431921","DOI":"10.3389\/fcell.2024.1431921","volume":"12","author":"Z Cheng","year":"2024","unstructured":"Cheng, Z. et al. Hepatocyte programmed cell death: the trigger for inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis. Front. Cell Dev. Biol. 12, 1431921 (2024).","journal-title":"Front. Cell Dev. Biol."},{"key":"1740_CR15","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccr.2012.04.026","volume":"21","author":"K Nikolaou","year":"2012","unstructured":"Nikolaou, K. et al. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 21, 738\u2013750 (2012).","journal-title":"Cancer Cell"},{"key":"1740_CR16","doi-asserted-by":"publisher","first-page":"e123294","DOI":"10.1172\/jci.insight.123294","volume":"5","author":"S Schuster-Gaul","year":"2020","unstructured":"Schuster-Gaul, S. et al. ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model. JCI Insight 5, e123294 (2020).","journal-title":"JCI Insight"},{"key":"1740_CR17","doi-asserted-by":"publisher","first-page":"648915","DOI":"10.1155\/2012\/648915","volume":"2012","author":"JB Chakraborty","year":"2012","unstructured":"Chakraborty, J. B., Oakley, F. & Walsh, M. J. Mechanisms and biomarkers of apoptosis in liver disease and fibrosis. Int. J. Hepatol. 2012, 648915 (2012).","journal-title":"Int. J. Hepatol."},{"key":"1740_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ebiom.2018.10.028","volume":"37","author":"H Wang","year":"2018","unstructured":"Wang, H. et al. Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis. eBioMedicine 37, 322\u2013333 (2018).","journal-title":"eBioMedicine"},{"key":"1740_CR19","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41418-024-01348-9","volume":"31","author":"C Peleman","year":"2024","unstructured":"Peleman, C. et al. Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease. Cell Death Differ. 31, 1113\u20131126 (2024).","journal-title":"Cell Death Differ."},{"key":"1740_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1172\/JCI200422422","volume":"114","author":"JD Browning","year":"2004","unstructured":"Browning, J. D. & Horton, J. D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114, 147\u2013152 (2004).","journal-title":"J. Clin. Invest."},{"key":"1740_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.freeradbiomed.2020.02.027","volume":"152","author":"F Ursini","year":"2020","unstructured":"Ursini, F. & Maiorino, M. Lipid peroxidation and ferroptosis: the role of GSH and GPx4. Free Radic. Biol. Med. 152, 175\u2013185 (2020).","journal-title":"Free Radic. Biol. Med."},{"key":"1740_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.freeradbiomed.2018.09.014","volume":"133","author":"TM Seibt","year":"2019","unstructured":"Seibt, T. M., Proneth, B. & Conrad, M. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic. Biol. Med. 133, 144\u2013152 (2019).","journal-title":"Free Radic. Biol. Med."},{"key":"1740_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02121-2","volume":"23","author":"Y He","year":"2025","unstructured":"He, Y. et al. From mechanisms to medicine: ferroptosis as a therapeutic target in liver disorders. Cell Commun. Signal. 23, 125 (2025).","journal-title":"Cell Commun. Signal."},{"key":"1740_CR24","doi-asserted-by":"publisher","first-page":"116512","DOI":"10.1016\/j.biopha.2024.116512","volume":"174","author":"W Zhang","year":"2024","unstructured":"Zhang, W. et al. GPX4, ferroptosis, and diseases. Biomed. Pharmacother. 174, 116512 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"1740_CR25","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/antiox13111336","volume":"13","author":"GC Park","year":"2024","unstructured":"Park, G. C. et al. Inhibiting ferroptosis prevents the progression of steatotic liver disease in obese mice. Antioxidants 13, 1336 (2024).","journal-title":"Antioxidants"},{"key":"1740_CR26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.freeradbiomed.2022.11.011","volume":"193","author":"SS Cho","year":"2022","unstructured":"Cho, S. S. et al. Ferroptosis contribute to hepatic stellate cell activation and liver fibrogenesis. Free Radic. Biol. Med. 193, 620\u2013637 (2022).","journal-title":"Free Radic. Biol. Med."},{"key":"1740_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.freeradbiomed.2025.02.031","volume":"231","author":"M Li","year":"2025","unstructured":"Li, M. et al. Artemether relieves liver fibrosis by triggering ferroptosis in hepatic stellate cells via DHHC12-mediated S-palmitoylation of the BECN1 protein. Free Radic. Biol. Med. 231, 120\u2013135 (2025).","journal-title":"Free Radic. Biol. Med."},{"key":"1740_CR28","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3168\/jds.2016-11647","volume":"100","author":"HB Shi","year":"2017","unstructured":"Shi, H. B. et al. Peroxisome proliferator-activated receptor delta facilitates lipid secretion and catabolism of fatty acids in dairy goat mammary epithelial cells. J. Dairy Sci. 100, 797\u2013806 (2017).","journal-title":"J. Dairy Sci."},{"key":"1740_CR29","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1194\/jlr.M001123","volume":"51","author":"K Ravnskjaer","year":"2010","unstructured":"Ravnskjaer, K. et al. PPAR\u03b4 is a fatty acid sensor that enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid-induced dysfunction. J. Lipid Res. 51, 1370\u20131379 (2010).","journal-title":"J. Lipid Res."},{"key":"1740_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-10-20","volume":"10","author":"I Paterniti","year":"2013","unstructured":"Paterniti, I. et al. Molecular evidence for the involvement of PPAR-\u03b4 and PPAR-\u03b3 in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. J. Neuroinflammation 10, 20 (2013).","journal-title":"J. Neuroinflammation"},{"key":"1740_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.4093\/dmj.2013.37.6.395","volume":"37","author":"C Corzo","year":"2013","unstructured":"Corzo, C. & Griffin, P. R. Targeting the peroxisome proliferator-activated receptor-gamma to counter the inflammatory milieu in obesity. Diabetes Metab. J. 37, 395\u2013403 (2013).","journal-title":"Diabetes Metab. J."},{"key":"1740_CR32","doi-asserted-by":"publisher","first-page":"105088","DOI":"10.1016\/j.ebiom.2024.105088","volume":"102","author":"C Peleman","year":"2024","unstructured":"Peleman, C., Francque, S. & Berghe, T. V. Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation. eBioMedicine 102, 105088 (2024).","journal-title":"eBioMedicine"},{"key":"1740_CR33","doi-asserted-by":"publisher","first-page":"e52280","DOI":"10.15252\/embr.202052280","volume":"23","author":"G Xing","year":"2022","unstructured":"Xing, G. et al. PPARalpha alleviates iron overload-induced ferroptosis in mouse liver. EMBO Rep. 23, e52280 (2022).","journal-title":"EMBO Rep."},{"key":"1740_CR34","doi-asserted-by":"publisher","first-page":"116856","DOI":"10.1016\/j.ejmech.2024.116856","volume":"279","author":"J Kim","year":"2024","unstructured":"Kim, J. et al. Discovery of the therapeutic potential of PPAR\u03b4 agonist bearing 1,3,4- thiadiazole in inflammatory disorders. Eur. J. Med. Chem. 279, 116856 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"1740_CR35","doi-asserted-by":"publisher","first-page":"101189","DOI":"10.1016\/j.xpro.2022.101189","volume":"3","author":"F Wang","year":"2022","unstructured":"Wang, F., Naowarojna, N. & Zou, Y. Stratifying ferroptosis sensitivity in cells and mouse tissues by photochemical activation of lipid peroxidation and fluorescent imaging. STAR Protoc. 3, 101189 (2022).","journal-title":"STAR Protoc."},{"key":"1740_CR36","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.3727\/096368915X686788","volume":"24","author":"AC Dusabineza","year":"2015","unstructured":"Dusabineza, A. C. et al. Hepatic stellate cells improve engraftment of human primary hepatocytes: a preclinical transplantation study in an animal model. Cell Transplant. 24, 2557\u20132571 (2015).","journal-title":"Cell Transplant."},{"key":"1740_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202309907","volume":"11","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. A membrane-targeting aggregation-induced emission probe for monitoring lipid droplet dynamics in ischemia\/reperfusion-induced cardiomyocyte ferroptosis. Adv. Sci. 11, e2309907 (2024).","journal-title":"Adv. Sci."},{"key":"1740_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06931-6","volume":"9","author":"JQ Liang","year":"2018","unstructured":"Liang, J. Q. et al. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling. Nat. Commun. 9, 4490 (2018).","journal-title":"Nat. Commun."},{"key":"1740_CR39","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/j.gastro.2011.09.049","volume":"142","author":"T Teratani","year":"2012","unstructured":"Teratani, T. et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 142, 152\u2013164 (2012).","journal-title":"Gastroenterology"},{"key":"1740_CR40","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1194\/jlr.M049429","volume":"55","author":"AB Singh","year":"2014","unstructured":"Singh, A. B. et al. A novel posttranscriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression. J. Lipid Res. 55, 1397\u20131407 (2014).","journal-title":"J. Lipid Res."},{"key":"1740_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/ATVBAHA.112.301131","volume":"34","author":"AB Singh","year":"2014","unstructured":"Singh, A. B. et al. The critical role of mRNA destabilizing protein heterogeneous nuclear ribonucleoprotein d in 3\u2032 untranslated region-mediated decay of low-density lipoprotein receptor mRNA in liver tissue. Arterioscler. Thromb. Vasc. Biol. 34, 8\u201316 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1740_CR42","doi-asserted-by":"publisher","first-page":"e0646","DOI":"10.1097\/HC9.0000000000000646","volume":"9","author":"T Yamazaki","year":"2025","unstructured":"Yamazaki, T., Cable, E. E. & Schnabl, B. Peroxisome proliferator-activated receptor delta and liver diseases. Hepatol. Commun. 9, e0646 (2025).","journal-title":"Hepatol. Commun."},{"key":"1740_CR43","doi-asserted-by":"publisher","first-page":"113869","DOI":"10.1016\/j.addr.2021.113869","volume":"176","author":"S Kumar","year":"2021","unstructured":"Kumar, S. et al. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis. Adv. Drug Deliv. Rev. 176, 113869 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1740_CR44","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3892\/mmr.2021.12003","volume":"23","author":"QN Cheng","year":"2021","unstructured":"Cheng, Q. N. et al. Interaction of non\u2011parenchymal hepatocytes in the process of hepatic fibrosis (review). Mol. Med. Rep. 23, 364 (2021).","journal-title":"Mol. Med. Rep."},{"key":"1740_CR45","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1158\/0008-5472.CAN-11-3317","volume":"72","author":"C Coulouarn","year":"2012","unstructured":"Coulouarn, C. et al. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res. 72, 2533\u20132542 (2012).","journal-title":"Cancer Res."},{"key":"1740_CR46","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.3390\/ijms20092180","volume":"20","author":"K Sato","year":"2019","unstructured":"Sato, K. et al. Intercellular communication between hepatic cells in liver diseases. Int. J. Mol. Sci. 20, 2180 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1740_CR47","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/HEP.0000000000000786","volume":"82","author":"X Wang","year":"2024","unstructured":"Wang, X., Zhang, L. & Dong, B. Molecular mechanisms in MASLD\/MASH-related HCC. Hepatology 82, 1303\u20131324 (2024).","journal-title":"Hepatology"},{"key":"1740_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/21691401.2024.2360008","volume":"52","author":"W Li","year":"2024","unstructured":"Li, W. & Yu, L. Role and therapeutic perspectives of extracellular vesicles derived from liver and adipose tissue in metabolic dysfunction-associated steatotic liver disease. Artif. Cells Nanomed. Biotechnol. 52, 355\u2013369 (2024).","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"1740_CR49","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.3390\/biomedicines11102808","volume":"11","author":"A Leszczynska","year":"2023","unstructured":"Leszczynska, A. et al. Extracellular vesicles as therapeutic and diagnostic tools for chronic liver diseases. Biomedicines 11, 2808 (2023).","journal-title":"Biomedicines"},{"key":"1740_CR50","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.3390\/biomedicines12122848","volume":"12","author":"X Zou","year":"2024","unstructured":"Zou, X. & Brigstock, D. Extracellular vesicles from mesenchymal stem cells: potential as therapeutics in metabolic dysfunction-associated steatotic liver disease (MASLD). Biomedicines 12, 2848 (2024).","journal-title":"Biomedicines"},{"key":"1740_CR51","doi-asserted-by":"publisher","first-page":"123321","DOI":"10.1016\/j.biomaterials.2025.123321","volume":"321","author":"H Cho","year":"2025","unstructured":"Cho, H. et al. Engineered extracellular vesicles with surface FGF21 and enclosed miR-223 for treating metabolic dysfunction-associated steatohepatitis. Biomaterials 321, 123321 (2025).","journal-title":"Biomaterials"},{"key":"1740_CR52","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/lifemeta\/loac035","volume":"1","author":"J Guo","year":"2022","unstructured":"Guo, J. et al. Mitochondria as multifaceted regulators of ferroptosis. Life Metab. 1, 134\u2013148 (2022).","journal-title":"Life Metab."},{"key":"1740_CR53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-020-00428-9","volume":"6","author":"HF Yan","year":"2021","unstructured":"Yan, H. F. et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct. Target. Ther. 6, 49 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1740_CR54","doi-asserted-by":"publisher","first-page":"717610","DOI":"10.3389\/fcell.2021.717610","volume":"9","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. The cytosolic DNA-sensing cGAS\u2013STING pathway in liver diseases. Front. Cell Dev. Biol. 9, 717610 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1740_CR55","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1097\/HEP.0000000000000388","volume":"78","author":"S Arumugam","year":"2023","unstructured":"Arumugam, S. et al. Mitochondrial DNA and the STING pathway are required for hepatic stellate cell activation. Hepatology 78, 1448\u20131461 (2023).","journal-title":"Hepatology"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01740-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01740-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01740-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:23:20Z","timestamp":1782912200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01740-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1740"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01740-0","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}